Myeloproliferative Disorders (MPD) Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The market is segmented by Type of MPD (Polycythaemia Vera, Polycythaemia Vera, Myelofibrosis, and Other Types of MPD), Treatment Type (Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Other Treatments), End User (Hospitals, Specialty Clinics, and Other End Users), and Geography

Market Snapshot

myeloproliferative disorders drug market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.9 %
 myeloproliferative disorders drug market size

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The global myeloproliferative disorders drug market is anticipated to grow significantly during the forecast period due to the increasing prevalence of the various myeloproliferative disorders, the presence of strong pipeline products, frequent product approvals, and growing R&D investments on the development of novel drugs for MPD Treatment market.

According to the National Organization for Rare Disorders (NORD), men are more likely affected than women with Polycythemia vera. The disorder is anticipated to affect around two people per 100,000 in the general population. It occurs most often in individuals over 60 years old but can affect individuals of any age.

However, side effects associated with chemotherapy medications might hamper the growth of the market studied.

Scope of the Report

Myeloproliferative disorders are also known as myeloproliferative neoplasms. These are the unique group of hematopoietic stem cell disorders that share in common mutations which continuously activate JAK2 (Janus kinase 2), an enzyme that normally stimulates the production of red blood cells, white blood cells (granulocytes, monocytes, basophils and eosinophils) and platelets. There are different types of MPDs, such as Myelofibrosis (MF), Polycythemia Vera (PV), and Essential thrombocythemia (ET), are the major types, among others.

By Type of MPD
Polycythaemia Vera
Essential Thrombocythemia
Other Types of MPD
By Treatment
Stem Cell Transplantation
Other Treatments
By End User
Specialty Clinics
Other End Users
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East & Africa
South Africa
Rest of Middle-East & Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Myelofibrosis Segment Holds Significant Share in the MPD Treatment Market

Myelofibrosis is a group of rare cancers of bone marrow in which the marrow is replaced by scar tissue and cannot make healthy blood cells. It is classified as a type of chronic leukemia and belongs to a group of blood disorders called myeloproliferative diseases. It is also called as primary myelofibrosis, chronic idiopathic myelofibrosis or myelosclerosis with myeloid metaplasia.

According to the National Organization for Rare Disorders (NORD), the true incidence of MF is not known but estimated to be approximately 1-1.5 per 100,000 people and is likely higher due to under-diagnosing and under-reporting.

Frequent product launches of the drugs for myelofibrosis treatment are expected to drive the segment in the market studied. For instance, in September 2019, Sierra Oncology Inc. received U.S. Food and Drug Administration (FDA) Fast Track designation approval to its momelotinib, a JAK1, JAK2 and ACVR1 inhibitor for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.

myeloproliferative disorders drug market share

North America Dominates the Global Myeloproliferative Disorders Treatment Market

North America dominates the global MPD treatment market owing to the increase in the prevalence of myelodysplastic syndrome, early adoption of the novel treatments, high R&D investments on the development of the novel drugs, and the presence of sophisticated healthcare infrastructure.

For instance, in August 2019, Celgene Corporation (Acquired by Bristol-Myers Squibb) received U.S. Food and Drug Administration (FDA) approval to its INREBIC (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

The Asia Pacific is expected to experience lucrative growth in the global myeloproliferative disorders treatment market due to the developing healthcare infrastructure, rapidly improving economic conditions, and promising regulatory environment for new treatment.

myeloproliferative disorders drug industry

Competitive Landscape

In the market studied, major players are focused on expanding their business in different areas by adopting various market strategies such as partnerships, collaborations, acquisitions, and mergers. Key developments in the market include - in January 2019, Takeda Pharmaceutical Company Limited completed the acquisition of Shire Plc, one of the major players in the event of novel drugs for the treatment of myeloproliferative disorders.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 High R&D Investments on Development of Novel Treatments for MPD

      2. 4.2.2 Strong Presence of Pipeline Drugs

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects Associated with Medications

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Type of MPD

      1. 5.1.1 Polycythaemia Vera

      2. 5.1.2 Essential Thrombocythemia

      3. 5.1.3 Myelofibrosis

      4. 5.1.4 Other Types of MPD

    2. 5.2 By Treatment

      1. 5.2.1 Chemotherapy

      2. 5.2.2 Immunotherapy

      3. 5.2.3 Stem Cell Transplantation

      4. 5.2.4 Other Treatments

    3. 5.3 By End User

      1. 5.3.1 Hospitals

      2. 5.3.2 Specialty Clinics

      3. 5.3.3 Other End Users

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East & Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East & Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie

      2. 6.1.2 Bristol-Myers Squibb

      3. 6.1.3 Incyte Corporation

      4. 6.1.4 Mylan NV

      5. 6.1.5 Novartis AG

      6. 6.1.6 Pfizer

      7. 6.1.7 Teva Pharmaceuticals

      8. 6.1.8 Takeda Pharmaceutical Company Limited

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Development

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Myeloproliferative Disorders (MPD) Treatment Market market is studied from 2018 - 2026.

The Myeloproliferative Disorders (MPD) Treatment Market is growing at a CAGR of 4.9% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Novartis AG , Bristol-Myers Squibb, Incyte Corporation, Takeda Pharmaceutical Company Limited, Mylan N.V. are the major companies operating in Myeloproliferative Disorders (MPD) Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!